High prevalence of the risk factors for QT interval prolongation and associated drug–drug interactions in coronary care units

References

• Gupta A, Lawrence AT, Krishnan K, et al. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 2007 Jun;153(6):891–899. PubMed PMID: 17540188.
   PubMed Web of Science ®Google Scholar
• Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2010 Mar 2;55(9):934–947. PubMed PMID: 20185054; PubMed Central PMCID: PMCPMC3057430; English.
   PubMed Web of Science ®Google Scholar
• Smithburger PL, Seybert AL, Armahizer MJ, et al. QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions. Expert Opin Drug Saf. 2010 Sep;9(5):699–712. PubMed PMID: 20377471; English.
   PubMed Web of Science ®Google Scholar
• Tisdale JE. What causes some patients with drug-induced QT interval prolongation to develop torsades de pointes but not others? The elusive missing link. Drugs Aging. 2014 Aug;31(8):577–579. PubMed PMID: 25023065; eng.
   PubMed Web of Science ®Google Scholar
• AZCERT. Arizona Center for Education and Research on Therapeutics (AZCERT). 2017 [cited 2017 May 15]. Available from: http://www.crediblemeds.org
   Google Scholar
• Wood AJ, Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013–1022.
   PubMed Web of Science ®Google Scholar
• Olivier P, Montastruc JL. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. Pharmacoepidemiol Drug Saf. 2006 Nov;15(11):808–812. PubMed PMID: 16700082; eng.
   PubMed Web of Science ®Google Scholar
• Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol. 2007 Jan;22(1):39–43. PubMed PMID: 17143043; eng.
   PubMed Web of Science ®Google Scholar
• Armahizer MJ, Seybert AL, Smithburger PL, et al. Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. J Crit Care. 2013 Jun;28(3):243–249. PubMed PMID: 23312127; eng.
   PubMed Web of Science ®Google Scholar
• Pickham D, Helfenbein E, Shinn JA, et al. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) Study. Crit Care Med. 2012 Feb;40(2):394–399. PubMed PMID: 22001585; eng.
   PubMed Web of Science ®Google Scholar
• Allen LaPointe NM, Curtis LH, Chan KA, et al. Frequency of high‐risk use of QT‐prolonging medications. Pharmacoepidemiol Drug Saf. 2006;15(6):361–368.
   PubMed Web of Science ®Google Scholar
• Gorard DA. Escalating polypharmacy. QJM: Mon J Assoc Phys. 2006 Nov;99(11):797–800. PubMed PMID: 17030528; eng.
   PubMed Web of Science ®Google Scholar
• Tisdale JE, Wroblewski HA, Overholser BR, et al. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US. Drug Saf. 2012 Jun 1;35(6):459–470. PubMed PMID: 22612851.
   PubMed Web of Science ®Google Scholar
• Smithburger PL, Kane-Gill SL, Seybert AL. Drug-drug interactions in cardiac and cardiothoracic intensive care units: an analysis of patients in an academic medical centre in the US. Drug Saf. 2010 Oct 1;33(10):879–888. PubMed PMID: 20812772; eng.
   PubMed Web of Science ®Google Scholar
• Micromedex. Micromedex Drug-Reax®. Greenwood Village (CO): Truven Health Analytics; 2017 [cited 2017 May 26]. Available from https://www.micromedexsolutions.com
   Google Scholar
• WHO. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2017. 2017 [cited 2017 Feb 2]. Available from: http://www.whocc.no/atc_ddd_index
   Google Scholar
• Fernandes FM, Silva EP, Martins RR, et al. QTc interval prolongation in critically ill patients: prevalence, risk factors and associated medications. PLoS One. 2018;13(6):e0199028. PubMed PMID: 29898002; PubMed Central PMCID: PMCPMC5999273.
   PubMed Web of Science ®Google Scholar
• Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):479–487. PubMed PMID: 23716032; PubMed Central PMCID: PMCPMC3788679; eng.
   PubMed Web of Science ®Google Scholar
• Etchegoyen CV, Keller GA, Mrad S, et al. Drug-induced QT interval prolongation in the intensive care unit. Curr Clin Pharmacol. 2017;12(4):210–222. PubMed PMID: 29473523.
   PubMed Web of Science ®Google Scholar
• Curtis LH, Ostbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003 Feb 1;114(2):135–141. PubMed PMID: 12586234; eng.
   PubMed Web of Science ®Google Scholar
• Moreno-Gutierrez PA, Gaviria-Mendoza A, Canon MM, et al. High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia. Br J Clin Pharmacol. 2016 Aug;82(2):504–511. PubMed PMID: 27060989; PubMed Central PMCID: PMCPMC4972167.
   PubMed Web of Science ®Google Scholar
• Goutelle S, Sidolle E, Ducher M, et al. Determinants of torsades de pointes in older patients with drug-associated long QT syndrome: a case-control study. Drugs Aging. 2014 Aug;31(8):601–609. PubMed PMID: 24923384; eng.
   PubMed Web of Science ®Google Scholar
• Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003 Nov;89(11):1363–1372. PubMed PMID: 14594906; PubMed Central PMCID: PMCPMC1767957; eng.
   PubMed Web of Science ®Google Scholar